Drugs / LEM-S401
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04707131 | Jul → Oct 2022 | keloid formation | Lemonex Inc. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LEM-S401 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04707131 ↗ |
| Action | Inhibit | “thereby inhibiting excessive collagen production.” PMID 40160160 ↗ Apr 2025 |
| Modality | Small interfering RNA (siRNA) | “LEM-S401, a novel siRNA therapeutic with DegradaBALL, a mesoporous silica nanoparticle-based delivery system.” PMID 40160160 ↗ Apr 2025 |
| Route | Subcutaneous | “LEM-S401 administered as subcutaneous injection” NCT04707131 ↗ |
| Target | CTGF | “LEM-S401 is designed to deliver siRNA targeting connective tissue growth factor (CTGF) to fibroblasts for treating hypertrophic scars and keloids” PMID 40160160 ↗ Apr 2025 |